Optimizing Treatment for Medication Adherence in Schizophrenia

Target Audience:

This activity is designed to meet the educational needs of psychiatrists, primary care physicians, nurses, pharmacists, and other healthcare practitioners caring for schizophrenic patients.

Program Overview

Appropriate educational initiatives aimed at understanding evolving roles of atypical antipsychotics, developing treatment plans that improve adherence and outcomes for patients with schizophrenia, quantifying the impact of non-adherence on quality of life, and discussing collaborative efforts between patients and caregivers will support effective care for those with schizophrenia. As educators, we have the opportunity to improve on our already high standards of care in schizophrenia in order to enhance patient outcomes and quality of life for this long-term condition.

Disclosure Of Unlabeled Use

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Faculty have indicated there is no such discussion.

Disclaimer

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

To Obtain CME/CE Credits:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME/CE credit.
  • You must score 70% or higher on the post-test to receive credit for this activity.
  • All other non-physician participants who successfully complete the post-test and evaluation will receive a certificate of participation or nursing certificate.

Course Viewing Requirements:

Internet Explorer 6 or greater (10 or above recommended), Firefox, Chrome or Safari 6 or greater.

MEDIUM: Internet

Estimated Time to Complete This Educational Activity: 60 minutes

For CE questions, please contact: Med Learning Group at info@medlearninggroup.com

Contact Med Learning Group for privacy and confidentiality policy statement information at:

http://www.medlearninggroup.com/privacy-policy/

Copyright: © 2013 Ultimate Medical Academy/CCM

Accreditation:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation:

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

Faculty Listing:

Activity Leader
S. Charles Schulz, MD
Professor and Head
Department of Psychiatry
University of Minnesota Medical School
Minneapolis, MN

CME Advisory Committee

Course Director/Course Reviewer
M. Susan Burke, MD, FACP
Clinical Assistant Professor, Internal Medicine
Thomas Jefferson University Medical School
Senior Advisor, Internal Medicine Clinical Care Center
Lankenau Hospital
Wynnewood, Pennsylvania

Planning Committee

Kelly Kraines
Director of CME/CE
Med Learning Group

Christopher Drury
The Quill Consulting

Margaret Governo, EdD, APRN BC
CCM Lead Nurse Planner
Ultimate Medical Academy

Subjects:

  • Schizophrenia

Objectives:

  • Discuss the evolving roles of atypical antipsychotics in the treatment of schizophrenia
  • Evaluate the various atypical antipsychotics and their effects on the full spectrum of schizophrenia symptoms
  • Motivate your schizophrenia patients to stay adherent to medication through follow-up, providing information, and involving other caregivers as needed
  • Describe how long-acting formulations of atypical antipsychotics could improve medication adherence

Financial Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate fair balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Faculty

S. Charles Schulz, MD
Disclosure: Dr. Schulz receives a Research Grant from AstraZeneca, Myraid/RBM, NIMH and Otsuka. He also receives Consulting Fees from Eli Lilly and Genentech.

M. Susan Burke, MD
Disclosure: Dr. Burke receives Consulting Fees from Iroko and Merck & Co., Inc.

Planning Committee

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Kelly Kraines of Med Learning Group has no relevant financial relationships to disclose.

Christopher Drury, of The Quill Consulting has no relevant financial relationships to disclose.

Margaret Governo, EdD, APRN BC has no relevant financial relationships to disclose.